Fig. 4

Construction and functional verification of Ab-γδ TCR/CAR-T cells that target ectopically expressed hMSH2 and NCL. a Schematic of Ab-γδ TCR (left) and CAR (right) molecules. b Western blotting was performed to evaluate the expression of Ab-γδ TCRs and CARs in 293 T cells with anti-TCR δ chain and anti-CD3ζ antibodies. c Representative flow cytometric plots of the ZsGreen signal showing the transduction efficacy. RTCA was performed to measure the cytotoxicity of hMSH2 Ab-γδ TCR/CAR-T cells d and NCL-Ab-γδ TCR-T cells e against tumor cells in vitro. The plot shows the statistical data at 24 h. The data are representative of three independent experiments and are expressed as the means ± SDs. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001; ns, p > 0.05, not significant. hMSH2-Ab-γδ TCR-T cells and hMSH2-CAR-T cells exhibited strong cytotoxic activity against tumor cells in the B-NDG mouse model. B-NDG mice implanted with SW480 cells were treated with Vector-αβ T cells, hMSH2-Ab-γδ TCR-T cells, or hMSH2-CAR-T cells. Tumor growth in every mouse at each time point was measured with a Vernier caliper. The tumor growth curve f and survival curve g of each group are shown. The arrow shows the time point for treatment. **, p < 0.01; ***, p < 0.001; ****, p < 0.0001; ns, p > 0.05, not significant. h NCL-Ab-γδ TCR-T cells exhibited strong cytotoxic activity against tumor cells in the B-NDG mouse model. B-NDG mice implanted with HepG2 cells were treated with MOCK-T cells, NCL-Ab-γδ TCR-T cells or NCL-CAR-T cells. Tumor growth in every mouse at each time point was measured with a Vernier caliper. The arrow shows the time point for treatment